FDA Approves Janssen’s Schizophrenia Injection Invega Trinza

Drug Industry Daily
A A
Janssen Pharmaceuticals plans to make its long-acting atypical schizophrenia therapy Invega Trinza commercially available by mid-June, following FDA approval Monday.

To View This Article:

Login

Subscribe To Drug Industry Daily